UniPharma

topics

Early Access Medicine

Early Access Medicine is tracked by UniPharma when it has a clear effect on sourcing, regulation, access, or commercial execution for pharma teams.

Related insights

Latest articles on Early Access Medicine

April 23, 2026

UK brings forward MHRA-NICE aligned pathway for earlier pharma access

The UK has brought forward its MHRA-NICE aligned pathway, tightening the link between licensing and HTA and changing launch planning for pharma companies.

Read insight
April 23, 2026

UK gives Early Access to Medicines Scheme a formal legal basis

The UK is putting EAMS into law, giving manufacturers and hospitals a clearer route for pre-approval access, evidence collection, and supply planning.

Read insight
April 23, 2026

French early access pathway shows strong uptake as HAS refines assessment criteria

France’s early access medicine pathway is moving quickly, with HAS tightening criteria in ways that matter for launch planning, evidence strategy, and time to funded access.

Read insight
April 23, 2026

UK ILAP awards first Innovation Passport for belzutifan

Belzutifan’s Innovation Passport shows how the UK’s ILAP can shape evidence planning, regulator alignment, and earlier access strategy for innovative medicines.

Read insight

Contact us

Need support with access, sourcing or regulated supply?

Bring us the access challenge, the shortage pressure or the regulated logistics brief. We will turn it into a clean operating plan.

Contact us View services